IMV Inc. is developing injectable cancer immune therapy using the company’s DPXTM technology. DPX is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect). DPX can be tailored to various cancers via the use of tumor specific components in the formula. The way by which this therapy exerts […]

Cancer afflicts 1 in 8 people worldwide. Recent advancements in bench-to-bedside translational research has resulted in numerous effective treatments. However, a harsh reality still exists in that only ~20% of patients respond positively to treatment. Not all cancers are created equal, which has led to these clinical complexities undermining treatment options. It is our goal […]

IMV Inc. is developing injectable cancer immune therapy using the company’s DPXTM technology. DPX is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect. The way by which this therapy exerts its effect is unclear but the translational team at IMV is determined to discover its mechanism of […]